Navigation Links
Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
Date:5/20/2008

ducted at approximately 150 centers worldwide to determine the efficacy of elesclomol in combination with paclitaxel for the treatment of patients with metastatic (Stage IV) melanoma.(9) Elesclomol has received Fast Track and Orphan Drug designation from the FDA for metastatic melanoma, and the Phase III SYMMETRY trial has completed a Special Protocol Assessment process with the FDA. Additional investigations to evaluate elesclomol as a therapy for other cancers are currently being planned.(9)

GSK in Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary 'bench to bedside' approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centres. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

About GlaxoSmithKline

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

About Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical s
'/>"/>

SOURCE GlaxoSmithKline; Synta Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
2. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
3. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
4. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
5. Amikacin Inhale Shows Promising Results in Phase II Study
6. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
7. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
8. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
9. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
10. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... LAWRENCE, Mass. , Aug. 1, 2014  NxStage Medical, ... innovative dialysis products, today announced that Jeffrey H. Burbank ... Financial Officer, will present at the 34 th Annual ... Boston, MA , on Wednesday, August 13 ... event will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... JUPITER, Fla. , Aug. 1, 2014 ... company whose patented and proprietary technologies are used to ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... for the second quarter ended June 30, 2014 after ... host a conference call that day at 5:00 p.m. ...
(Date:7/31/2014)... , July 31, 2014  According to data ... Services, the 2015 average monthly Medicare Part D premium ... far lower than was originally projected, the Pharmaceutical Care ... D program continues to be a bright spot in ... choices in each region and using cutting edge, cost-saving ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... GeneXpert(R) System ... ... today announced the U.S. Food & Drug Administration (FDA) categorized,Cepheid,s ... Clinical Laboratory Improvement Amendments (CLIA).,The new test is designed for ...
... Michael J. Fox,Foundation today announced the availability of ... toward transformative treatments and a cure for,Parkinson,s disease., ... researchers through the,Foundation,s Pipeline Programs, five separate initiatives ... drug development pipeline. This includes,early-stage discovery research, translational ...
Cached Medicine Technology:Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 2Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 3Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 4Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 2Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 3Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 4
(Date:8/1/2014)... NJ (PRWEB) August 01, 2014 ... web portal that aims to empower patients and ... in their health care by providing easy, secure ... Portal gives patients instant, web-based access to their ... and radiology results, medications, allergies, demographic information, visit ...
(Date:8/1/2014)... procedures have grown in popularity as more and more ... toxin generally known as BOTOX use ... have emerged to perform procedures utilizing this and other ... from the Division of Plastic Surgery Presbyterian Hospital in ... University in New York have assessed the capability of ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 St. Christopher's ... in an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , St. Christopher's Hospital ... services for children from birth through 21 years of ... several of the hospital's specialties, including autism and childhood ...
(Date:8/1/2014)... Narconon Arrowhead recently celebrated the occasion ... drug rehab center located in the small town of ... is the flagship drug rehab center in the Narconon ... for services there. Now, with such a long track ... as well as client reviews showing the effectiveness of ...
(Date:8/1/2014)... TX (PRWEB) August 01, 2014 Delta ... the Year for its outstanding commitment to St. Jude ... the hospital since 1999 and pledging to raise another ... combat childhood cancer and other deadly diseases. , ... any single partner in St. Jude history. Specifically, it ...
Breaking Medicine News(10 mins):Health News:Chilton Medical Center Launches Online Patient Portal 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 2Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 3
... that vitamin C was vital for good health and could ... ,Dr Margret Vissers, from Otago University's Free Radical Research ... vitamin C was a vital part of healthy living and ... had a cold. ,"I've found that vitamin C ...
... nerve cells in the brain and lead to depression, according to ... and Science in North Chicago. ,The team led by Daniel ... rats for 20 minutes. The older rats quickly cornered, pinned down ... ,The younger rats became fearful and acted depressed in the ...
... below seven is fast depleting, which has sent the Ministry of ... Company CSL had stopped the production of the Tet-tox vaccine in ... is just enough to last till the end of this month. ... drugs will have to be used by those who are in ...
... New research suggests that a child’s race may ... tobacco toxins associated with environmental tobacco smoke (ETS). ... asthma, who are exposed to ETS, have significantly ... counterparts. ,“African American children suffer from ...
... question of bloodshot eyes anymore. After sleepless nights, a person’s ... has been found//. ,Sleep deprivation lowers metabolic ... colleagues at Walter Reed Army Institute of Research, report in ... group of volunteers to two sleepless nights, they found that ...
... Patients can start using their mobile phones when the ban ... in the hospitals because it was believed// that its electromagnetic ... per the directive issued from the Department of Health, cell ... equipments. ,This announcement has brought in cheer ...
Cached Medicine News:Health News:Vitamin C Could Help in Curbing Cancer 2Health News:Race Affects Tobacco Absorption in Children 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: